SLGL (Sol-Gel Technologies) FCF Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Sol-Gel Technologies FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sol-Gel Technologies's Free Cash Flow for the three months ended in Jun. 2024 was $0.00 Mil. Sol-Gel Technologies's Revenue for the three months ended in Jun. 2024 was $5.43 Mil. Therefore, Sol-Gel Technologies's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, Sol-Gel Technologies's current FCF Yield % is -91.30%.

The historical rank and industry rank for Sol-Gel Technologies's FCF Margin % or its related term are showing as below:

SLGL' s FCF Margin % Range Over the Past 10 Years
Min: -19006.98 Med: -292.9 Max: -25.05
Current: -272.36

During the past 9 years, the highest FCF Margin % of Sol-Gel Technologies was -25.05%. The lowest was -19006.98%. And the median was -292.90%.

SLGL's FCF Margin % is ranked worse than
59.52% of 1050 companies
in the Biotechnology industry
Industry Median: -143.325 vs SLGL: -272.36

Sol-Gel Technologies FCF Margin % Historical Data

The historical data trend for Sol-Gel Technologies's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sol-Gel Technologies FCF Margin % Chart

Sol-Gel Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-100.84

-292.90

-25.05

-248.65

-1,149.55

Sol-Gel Technologies Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sol-Gel Technologies's FCF Margin %

For the Biotechnology subindustry, Sol-Gel Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sol-Gel Technologies's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Sol-Gel Technologies's FCF Margin % falls into.

Sol-Gel Technologies FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Sol-Gel Technologies's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-17.864	/	1.554
	=	-1,149.55 %

Sol-Gel Technologies's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	0	/	5.433
	=	0.00 %

Sol-Gel Technologies FCF Margin % Related Terms

Thank you for viewing the detailed overview of Sol-Gel Technologies's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sol-Gel Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sol-Gel Technologies Ltd (NAS:SLGL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

4SG:Germany

Address

7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650

Website

https://www.sol-gel.com

Sol-Gel Technologies Ltd is a clinical-stage specialty pharmaceutical company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.